No images? Click here ![]() Remuneration-related restrictions on government financing arrangementsThe government yesterday announced updates to the Coronavirus Large Business Interruption Loan Scheme (CLBILS) and the Covid Corporate Financing Facility (CCFF). In the case of the CLBILS the maximum loan size is to be increased from £50 million to £200 million. However, any companies that wish to borrow more than £50 million will “be subject to restrictions on dividend payments, senior pay and share buy-backs during the period of the loan, including a ban on dividend payments and cash bonuses, except where they were previously agreed.” The announcement added that borrowers “cannot pay any cash bonuses or award any pay rises to senior management (including the board) except where they were a) declared before the CLBILS loan was taken out, b) is in keeping with similar payments made in the preceding 12 months, and c) does not have a material negative impact on the borrower’s ability to repay the loan.” A similar announcement was made by HM Treasury that companies wishing to draw from the CCFF for a term longer than 12 months will also be required to sign a letter “that commits to showing restraint on the payment of dividends and other capital distributions and on senior pay during the period in which their commercial paper is outstanding”. HM Treasury and the Bank of England have also decided to publish the names of any businesses that have drawn under the CCFF. FIT comment These announcements echo the pressure that the government put on regulated financial services businesses to demonstrate restraint regarding dividends, share buyback and cash bonuses in late March. It is therefore not surprising that similar expectations have now been set for the CLBILS and CCFF (albeit subject to a number of caveats). Perhaps the only surprise is that these new conditions have only just been announced in mid-May, two months after the arrangements were first announced. Further details are expected to be announced next week, but it is also worth noting some of the details set out in the announcements:
These are just some of the questions that could be raised and, until the detailed requirements are determined, it is difficult to assess to what extent these new restrictions will ‘bite’. That said, the political intent is clear – companies using the CLBILS or CCFF for large amounts or longer periods will be expected to demonstrate constraint on senior executive pay. In reality, most remuneration committees will already be well aware of the political pressure surrounding executive pay in the context of the Covid pandemic (in particular see our recent briefing regarding the recently issued Investment Association guidance). Any company considering using either the CLBILS or CCFF would be well advised to consider the ramifications for executive pay before using either funding arrangement. Even for companies not seeking such finance, this perhaps heightens the increasingly unsympathetic attitude coming from various institutional shareholders in recent weeks. These announcements also raise the question of whether similar conditions might be applied to other forms of government support, such as the Job Retention Scheme (JRS). We understand that such requirements were included when the financing of private hospitals was passed to the NHS. We are not aware of any plans to do so, but some commentators have already raised this and it would not be entirely surprising if this condition was added for further extensions of the JRS. Compensation practice in financial services firms Earlier this month the Financial Stability Board (FSB) published a summary of a workshop held in November 2019 to discuss implementation of compensation principles by large banks, insurance and asset management firms. The conclusions of the summary are particularly relevant to reward professionals in FS-businesses, but a number of notable general points also emerge. Malus and clawback
Risk alignment
Governance
FIT comment Even though it reflects comments made before the pandemic emerged, this summary is required reading for reward professionals in FS-businesses. We think it also offers a number of useful insights for those working outside the FS industry as it signals the ‘direction of travel’ regarding compensation practices for large businesses. In particular, we agree with the comments made regarding malus and clawback. This remains an area where companies are cautious to apply provisions. However, we anticipate that as similar provisions are now standard for UK listed companies their application is likely to increase and become more established. If you wish to discuss anything arising from this briefing, please ask your usual contact at FIT or call us on 020 7034 1111 or email us at Info@fit-rem.com. Rory Cray Darrell Hare Matt Higgins John Lee Sahul Patel Iain Scott Katharine Turner This paper is intended to be a summary of key issues but is not comprehensive and does not constitute advice. No legal responsibility is accepted as a result of reliance on the contents of this paper. This email is confidential. If you are not the intended recipient, please delete the email and do not use it in any way. FIT Remuneration Consultants LLP (FIT) does not accept or assume responsibility for any use of or reliance on this email by anyone, other than the intended addressee to the extent agreed in the relevant contract for the matter to which this email relates (if any). Consistent with data protection regulations, if you would like to review our records relating to your contact details or to request their removal from our systems, please contact us at info@fit-rem.com. While all reasonable care has been taken to avoid the transmission of viruses, it is the responsibility of the recipient to ensure that the onward transmission, opening or use of this message and any attachments will not adversely affect its systems or data. No responsibility is accepted by FIT in this regard. FIT is a limited liability partnership registered in England under registered number OC364396, with its registered address at 1 Duke Street, London, W1U 3EA. |